In vivo, A2BR blockade also reversed immune suppression in the tumor microenvironment by reducing levels of IL-10, MCP-1, and MDSCs in melanoma lesions and increasing the frequency of CD8+ T lymphocytes and NK cells, and increasing the levels of Th1-like cytokines [42]. Here, CD8A is linked to melanoma.